Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal…

Bristol-Myers Squibb is really racking up the cancer pacts as today it pens another deal for its PD-1 checkpoint inhibitor Opdivo (nivolumab)--this time to be…

The first spinoff from Cydan, an orphan disease incubator created by Pfizer Ventures and New Enterprise Associates, has nabbed $17 million to bump up its…

Tobira Therapeutics fell by about half in premarket trading on news that its Phase IIb trial to treat nonalcoholic steatohepatitis (NASH) failed to meet the…

California upstart Tricida has raised its highest level of cash to date with a $55 million Series C funding round backed by major biotech VC players.

Bristol-Myers Squibb will team up with AbbVie to run an early-stage lung cancer study combining BMS’ marketed checkpoint inhibitors with AbbVie’s experimental…

The FDA has designated Morphochem’s MCB3837 as a Qualified Infectious Disease Product and simultaneously put the antibiotic on its regulatory fast-track…

The FDA is not happy with Merck’s monoclonal antibody Clostridium difficile candidate and is demanding more data and analyses from its trials before it can…